VEGFA and urinary bladder carcinoma: These findings advocate for further studies to measure how VEGF influences bladder cancer’s immune landscape and to validate its clinical potential as a biomarker or therapeutic target, possibly through anti-VEGF agents that disrupt both angiogenesis and immune signaling pathways [103,104].